Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer
原文： 2022 年 发布于
Arch Ital Urol Androl
33 卷 第 2 期 e30380
浏览量：192次
作者：
Lai L. Y.
Tafuri S. M.
Ginier E. C.
Herrel L. A.
Dahm P.
Maisch P.
Lane G. I.
作者单位：
Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka. Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya kmatsuo@aichi-cc.jp. Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya. Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya. Department of Epidemiology and Preventive Medicine, Gifu University Graduate School of Medicine, Gifu. Center for Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka. Department of Epidemiology, Radiation Effects Research Foundation, Hiroshima. Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga. Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo. Division of Epidemiology, Department of Public Health and Forensic Medicine, Tohoku University Graduate School of Medicine, Sendai. Department of Epidemiology and International Health, International Clinical Research Center, National Center for Global Health and Medicine, Tokyo. Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo. Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo AXA Department of Health and Human Security, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
归属分类：
膀胱肿瘤治疗及预后证据
DOI：
10.18632/oncotarget.23451
关键词：
Cisplatin/adverse effects
Humans
*Immunotherapy/adverse effects/methods
*Muscles/pathology
*Neoadjuvant Therapy/adverse effects
Neoplasm Staging
*Urinary Bladder Neoplasms/drug therapy/pathology/therapy
chemoimmunotherapy
immunotherapy
meta-analysis
muscle-invasive bladder cancer (MIBC)
neoadjuvant
commercial or financial relationships that could be construed as a potential
conflict of interest.
Background: Several studies have investigated the potential role of the apparent diffusion coefficient (ADC) value of diffusion-weighted magnetic resonance imaging as a biomarker of high-grade and invasive bladder cancer. Methods: PubMed and the Cochrane Library were systematically searched in September 2021 to extract studies that evaluated the associations between ADC values, pathological T stage, and histological grade bladder cancers. The diagnostic performance of ADC values in detecting muscle-invasive bladder cancer (MIBC) and high-grade disease was systematically reviewed. Results: Six studies were included in this systematic review. MIBC showed significantly lower ADC values than non-muscle-invasive bladder cancer (NMIBC) in all six studies. The median (range) sensitivity, specificity, and area under the curve (AUC) of ADC values to detect MIBC among the four eligible studies were 73.5% (68.8-90.0%), 79.9% (66.7-84.4%), and 0.762 (0.730-0.884), respectively. Similarly, high-grade disease showed significantly lower ADC values than did low-grade disease in all four eligible studies. The median (range) sensitivity, specificity, and AUC of ADC values for detecting high-grade disease among the three eligible studies were 75.0% (73.0-76.5%), 95.8% (76.2-100%), and 0.902 (0.804-0.906), respectively. Conclusions: The ADC value is a non-invasive diagnostic biomarker for discriminating muscle-invasive and high-grade bladder cancer.